Followers | 826 |
Posts | 119448 |
Boards Moderated | 15 |
Alias Born | 09/05/2002 |
Saturday, May 13, 2017 4:57:05 PM
[New entries for M710 phase-1 trial, USPTO ruling
on ABBV’s ‘135 Humira patent, and CAFC ruling on
BMY’s Orencia patent; correction re date of Lovenox
patent retrial in US District Court.]
Copaxone (Glatopa) program
• 2017(?): Expected FDA approval of NVS/MNTA’s 40mg-Copaxone ANDA. On 2/17/17, MNTA reported that the ANDA approval was held up due to an FDA compliance issue at PFE’s fill/finish facility, which NVS/MNTA are using for Glatopa (#msg-128816545). Approval apparently can’t happen until PFE fixes all compliance issued at this site.
• 2017(?): Commercial launch of 40mg Glatopa. Having won the 40mg-Copaxone patent case in the US Court of Appeals, NVS/MNTA will almost certainly launch 40mg Glatopa as soon as they have FDA approval (#msg-124820193).
(Although there are other companies with 40mg-Copaxone ANDAs under FDA review, only NVS/MNTA has received FDA approval for the original 20mg formulation. The 20mg and 40mg formulations are identical except for the concentration of drug in the syringe.)
FoB program
• May 2017: USPTO ruling on ABBV’s ‘135 Humira dosing patent. (The IPR was brought by CHRS, but it affects all companies seeking to commercialize Humira FoBs in the US market.)
• Mid 2017: Submit 351(k) FDA application for Humira FoB, which is designated M923 and is wholly owned by MNTA. (Projected US launch of M923 is in 2018, subject to patent litigation—see #msg-118781959.)
• Timing unknown—probably after 351(k) submission: Out-license or commercial partnership for M923.
• 2H17: Report phase-1 data for Orencia FoB, which is designated M934 is and the lead compound in the 50/50 FoB partnership between MNTA and MYL (#msg-126247535). The phase-1 trial started in Nov 2016 (#msg-126247535).
• Late 2017/early 2018: Disclosure of identity of M710 (the second FoB compound in the MNTTA-MYL partnership) and start of phase-1 trial.
• Apr 2018: CAFC ruling on BMY’s Orencia patent, which MNTA attempted to challenge via an IPR.
Proprietary autoimmune program
• 2H17: Report data from SAD and MAD portions of phase-1 trial of M281, an anti-FcRn mAb wholly owned by MNTA.
• 2H17: Start phase-1 trial of M230, an Fc-receptor compound partnered with CSL (#msg-127656306).
Lovenox program
• 2H17: US District Court retrial of NVS/MNTA vs AMPH on infringement of MNTA’s Lovenox patents, which could result in substantial damages payable to NVS/MNTA. (The Appellate Court remanded the case to the District Court on 11/10/15, finding that the defendant, Amphastar, is not protected by the Hatch-Waxman Safe Harbor: #msg-118404904, #msg-115468100.)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM